Regulation · Anti-doping

Is MOTS-c banned
in sport?

In every sport that follows the World Anti-Doping Code, one rulebook decides: WADA’s Prohibited List. MOTS-c sits in S4, its hormone and metabolic modulators class, not in the catch-all class S0, and the difference matters.

Short answerRegulation · 7 min read · Updated 18 Nov 2026

Yes. WADA’s Prohibited List names MOTS-c in class S4.4.1, among activators of the AMP-activated protein kinase (AMPK), and S4 substances are prohibited in competition and out of it. MOTS-c has been named there since the 2025 List took effect on 1 January 2025. Substances in S4.4 are non-Specified, and USADA calls a therapeutic use exemption for it “highly unlikely”.

Key takeaways

  • The 2026 and 2027 Lists name “mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)” in S4.4.1, metabolic modulators, prohibited at all times.
  • WADA added MOTS-c as an example in the 2025 List; UK Anti-Doping said that year’s new examples were “additional examples of substances that are already prohibited”.
  • Because S4 addresses it, MOTS-c is not an S0 substance: substances in S4.4 are non-Specified, while everything in S0 is Specified.
  • Under the 2021 Code, presence or use of a non-Specified Substance carries four years unless the athlete establishes the violation was not intentional; the 2027 Code keeps four years as the starting point.
  • USADA and Sport Integrity Australia both say a therapeutic use exemption is unlikely.

01What does the WADA Prohibited List say about MOTS-c?

The Prohibited List is a mandatory International Standard under the World Anti-Doping Code, revised every year. MOTS-c sits in class S4, hormone and metabolic modulators.

The 2026 List, in force since 1 January 2026, heads S4 “PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)” and says: “Prohibited substances in classes S4.1 and S4.2 are Specified Substances. Those in classes S4.3 and S4.4 are non-Specified Substances.” Under S4.4, metabolic modulators, entry S4.4.1 covers “Activators of the AMP-activated protein kinase (AMPK), e.g. … (BAM15), AICAR, mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)”. AMPK is an enzyme that senses a cell’s energy state. The same entry lists PPARδ agonists such as GW1516 and Rev-erbα agonists such as SR9009.

Why not S0? Class S0, non-approved substances, covers “any pharmacological substance which is not addressed by any of the subsequent sections of the List” and has no current approval for human therapeutic use. MOTS-c is addressed by S4, so S4’s rules apply to it. The difference matters. Everything in S0 is a Specified Substance; substances in S4.4 are not.

ListIn forceMOTS-cS4.4.1 wording
20241 Jan 2024Not namedActivators of AMPK, “e.g. AICAR”, with PPARδ and Rev-erbα agonists
20251 Jan 2025Named; WADA: “added as an example”AMPK activators, e.g. AICAR, MOTS-c
20261 Jan 2026NamedAMPK activators, e.g. BAM15, AICAR, MOTS-c
20271 Jan 2027NamedSame AMPK entry; seladelpar and SLU-PP-332 and SLU-PP-915 added elsewhere in S4.4.1

02When was MOTS-c added, and was it prohibited before?

WADA’s Executive Committee approved the 2025 List on 12 September 2024. WADA published it on 25 September 2024, and it took effect on 1 January 2025. WADA’s explanatory note for that List says: “Mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) was added as an example of an AMP-activated protein kinase activator.”

Naming it did not create the prohibition, by UK Anti-Doping’s account. Its summary of the 2025 List gave MOTS-c among the year’s new examples and said: “Please note that these are not new substances being added to the 2025 List for the first time but are additional examples of substances that are already prohibited.” FDA staff’s 2026 briefing adds that the Global Drug Reference Online database (Global DRO) listed MOTS-c as a prohibited substance when FDA consulted it on 20 March 2024, drawing on the 2024 List’s hormone and metabolic modulators class.

DateWhat happened
2019The anti-doping laboratory at the German Sport University Cologne publishes a mass-spectrometry method for MOTS-c in plasma “for doping control purposes”, validated to WADA’s laboratory standard (Knoop, Rapid Communications in Mass Spectrometry).
20 Mar 2024FDA staff consult Global DRO, which lists MOTS-c as prohibited, drawing on the 2024 List’s hormone and metabolic modulators class (the access date in FDA’s 2026 briefing).
12 Sep 2024WADA’s Executive Committee approves the 2025 List.
25 Sep 2024WADA publishes the 2025 List, with MOTS-c named in S4.4.1.
1 Jan 2025The 2025 List takes effect.
1 Jan 2026The 2026 List takes effect, MOTS-c still named.
1 Jan 2027The 2027 List and the 2027 World Anti-Doping Code take effect.

03What follows for a non-Specified Substance under the Code?

The List decides what is prohibited. The World Anti-Doping Code decides what counts as a violation and what follows. These are the 2021 Code’s articles, which apply until the 2027 Code takes effect on 1 January 2027.

1
Presence in a sample (Article 2.1)

It is each athlete’s “personal duty to ensure that no Prohibited Substance enters their bodies”, and “it is not necessary that intent, Fault, Negligence or knowing Use on the Athlete’s part be demonstrated”.

2
Use or attempted use (Article 2.2)

A violation does not need a positive test. “The success or failure of the Use or Attempted Use of a Prohibited Substance or Prohibited Method is not material.”

3
Possession (Article 2.6)

Possession of a substance prohibited out of competition is a violation unless the athlete establishes that it is consistent with a therapeutic use exemption “or other acceptable justification”.

4
Sanction (Article 10.2)

For a non-Specified Substance, the period of ineligibility is four years unless the athlete “can establish that the anti-doping rule violation was not intentional” (Article 10.2.1.1). Otherwise it is two years (Article 10.2.2), subject to the Code’s reductions.

Substances in S0 are Specified, a different footing: for them the default is two years unless the anti-doping organisation establishes intent.

From 1 January 2027. The 2027 Code keeps four years as the starting point for presence or use of a non-Specified Substance and sets out when it may be reduced (Article 10.2.1). Possession has its own scale (Article 10.2.5).

04Can an athlete get a therapeutic use exemption for MOTS-c?

The anti-doping bodies we read say it is unlikely. USADA: “It is highly unlikely an athlete would get a TUE approved for MOTS-c because there is no approved therapeutic use for this experimental drug.” Sport Integrity Australia, on unapproved peptides in general: “A TUE is unlikely to be granted for an unregistered medicine”. MOTS-c has no FDA approval, and FDA staff found no MOTS-c product authorised by the European Medicines Agency: is MOTS-c legal in the US?

CountryBodyWhat it has said about MOTS-c
United KingdomUK Anti-DopingAmong the 2025 List’s new examples, which it called “additional examples of substances that are already prohibited”.
AustraliaSport Integrity Australia“Many unapproved peptides are prohibited in sport”; MOTS-C is among its “common examples”. Possession or use can lead to an anti-doping rule violation and a ban.
United StatesUSADA“prohibited at all times under Section 4.4 Metabolic Modulators, 4.4.1”; “explicitly listed”. Athletes should be “extremely wary” of experimental peptides sold with “for research purposes only” labels.

National medicines law does not move the sports listing. The US HHS compounding policy of October 2026, which names MOTS-c, concerns licensed US compounders, not anti-doping rules. Australia and the UK: is MOTS-c legal in Australia? and is MOTS-c legal in the UK?

05What changes in 2027?

WADA’s 2027 List, in force from 1 January 2027, keeps MOTS-c in S4.4.1. Its explanatory note records new S4 examples: seladelpar as a PPAR-delta agonist, and SLU-PP-332 and SLU-PP-915 as metabolic modulators. It also adds “peptides” to the S0 examples, noting that many unapproved peptides “fall under the S0 (Non-Approved Substances) class, or other classes (such as S2 or S4)”. It adds: “Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health.”

For MOTS-c nothing changes on the List: it was named before and is named still. The 2027 Code, effective the same day, restructures how sanction lengths are set (above). How the List treats other research peptides: peptides and anti-doping.

06What we don’t know

How many cases have involved MOTS-c. We have not counted anti-doping cases by substance.

Why WADA named it in 2025. The explanatory note records the addition but does not set out the evidence behind it.

The 2027 Code in full. We read the articles cited here, not the whole Code.

The research on MOTS-c is in our MOTS-c research guide and our MOTS-c research overview. Changes are logged in our regulatory changelog.

This is a plain-English summary of public documents, checked on 18 Nov 2026. It is not legal advice, and athletes should check with their national anti-doping organisation.

RefSources

  1. World Anti-Doping Agency. The 2026 Prohibited List: introduction, S0 and S4 (pp. 3–4, 10–11). International Standard, in force 1 Jan 2026 (file 2026list_en_final_clean_september_2025.pdf); read 18 Nov 2026. www.wada-ama.org/sites/default/files/2025-09/2026list_en_fin…
  2. World Anti-Doping Agency. The 2027 Prohibited List: S0 and S4 (S4.4.1). International Standard, takes effect 1 Jan 2027 (file 2027list_en_final_clean_4_nov_2026.pdf); read 18 Nov 2026. www.wada-ama.org/sites/default/files/2026-11/2027list_en_fin…
  3. World Anti-Doping Agency. The 2025 Prohibited List, S4.4.1. International Standard, in force 1 Jan 2025; read 18 Nov 2026. www.wada-ama.org/sites/default/files/2024-09/2025list_en_fin…
  4. World Anti-Doping Agency. The 2024 Prohibited List, S4.4.1. International Standard, in force 1 Jan 2024; read 18 Nov 2026. www.wada-ama.org/sites/default/files/2023-09/2024list_en_fin…
  5. World Anti-Doping Agency. Summary of Major Modifications and Explanatory Notes, 2025 Prohibited List (S4). Undated in its text (the file name carries 11 Sep 2024); read 18 Nov 2026. www.wada-ama.org/sites/default/files/2024-09/2025_list_expla…
  6. World Anti-Doping Agency. WADA publishes 2025 Prohibited List. News release, 25 Sep 2024 (ExCo approval 12 Sep 2024); read 18 Nov 2026. www.wada-ama.org/en/news/wada-publishes-2025-prohibited-list
  7. World Anti-Doping Agency. Summary of Major Modifications and Explanatory Notes, 2027 Prohibited List (S0, S4). Undated in its text (the file name carries 17 Aug 2026); read 18 Nov 2026. www.wada-ama.org/sites/default/files/2026-09/2027_list_expla…
  8. World Anti-Doping Agency. World Anti-Doping Code 2021, Articles 2.1, 2.2, 2.6 and 10.2. Code text; read 18 Nov 2026. www.wada-ama.org/sites/default/files/resources/files/2021_wa…
  9. World Anti-Doping Agency. World Anti-Doping Code 2027, Article 10.2 (effective 1 Jan 2027). Code text, October 2026 version; read 18 Nov 2026. www.wada-ama.org/sites/default/files/2026-10/2027_world_anti…
  10. UK Anti-Doping. 2025 Prohibited List: Summary of Changes. News page, undated in its text (it describes the 2025 List, published 25 Sep 2024); read 18 Nov 2026. www.ukad.org.uk/news/2025-prohibited-list-summary-changes
  11. USADA. What is the MOTS-c peptide? Web page, undated in its text; read 18 Nov 2026. www.usada.org/spirit-of-sport/what-is-mots-c-peptide/
  12. Sport Integrity Australia. Peptides. Substance education page; read on the Internet Archive capture of 5 Nov 2026, the newest (sportintegrity.gov.au did not respond). www.sportintegrity.gov.au/what-we-do/anti-doping/substance-e…
  13. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee, 23–24 July 2026: MOTS-c-related bulk drug substances, pp. 20–21 (Global DRO, accessed 20 Mar 2024; EMA). Advisory committee briefing, 2026; read 18 Nov 2026. www.fda.gov/media/193347/download
  14. Knoop A, Thomas A, Thevis M. Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes. Rapid Commun Mass Spectrom, 2019;33(4):371–380. PMID 30394592 (abstract read). pubmed.ncbi.nlm.nih.gov/30394592/

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Is MOTS-c prohibited only in competition?

No. Class S4 is prohibited both in competition and out of competition.

Is MOTS-c a Specified Substance?

No. The List says substances in classes S4.3 and S4.4 are non-Specified. Under the 2021 Code that means four years for presence or use unless the athlete establishes the violation was not intentional.

When was MOTS-c added to the WADA list?

WADA named it as an example in S4.4.1 in the 2025 List, published on 25 September 2024 and in force from 1 January 2025. UK Anti-Doping described that year’s new examples as substances already prohibited.

Is MOTS-c in class S0?

No. S0 covers substances not addressed by any later section of the List, and MOTS-c is addressed in S4.4.1, metabolic modulators.

Can anti-doping laboratories detect MOTS-c?

The anti-doping laboratory in Cologne published a mass-spectrometry method for MOTS-c in plasma in 2019, validated to WADA’s laboratory standard.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page